Q-omics provides the consensus-scored MIR603 profile across patient tissues and cancer cell-line models. MIR603 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR603 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, MIR603 RNA expression shows 8,645 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight MESO, BRCA, and CCRCC as cancer lineages where MIR603 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR603 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR603 survival associations across molecular data types. MIR603 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR603 RNA expression–survival associations across cancer types. High MIR603 expression shows unfavorable associations in MESO, COAD, PAAD, DLBC, KIRC and UCEC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR603 RNA expression.
This table summarizes MIR603 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR603. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR603 shows lower tumor expression in BRCA and THCA. The BRCA box plot shows higher MIR603 RNA expression in normal versus tumor tissue (log2 FC = −0.308, t-test p = .049).
This table shows molecular features associated with MIR603 in patient tissues and cancer cell lines. In patient samples, MIR603 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
